Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: alzheimer's treatment + alzheimers + alzheimer's  Related to the article below (Last Update: 8/5/2008)


ChattahBox
A Second Chance to Buy Wyeth?
Barron's - Aug 3, 2008
WYETH AND ITS IRISH PARTNER, ELAN, TUESDAY UNVEILED EAGERLY awaited details of a Phase II clinical trial of a promising Alzheimer's drug, bapineuzumab. ...
Wyeth, Elan Fall on Doubts Raised by Alzheimer's Test (Update1) Bloomberg
Local docs see 'ray of hope' in Alzheimer's research nwitimes.com
Intellect Neurosciences, Inc. Obtains Pivotal European Patent ... MarketWatch
CNNMoney.com - Bloomberg
all 300 news articles »  ELN - PINK:ELNCF - OTC:ILNS

RTE.ie
MS drug fear sends Elan shares crashing
Belfast Telegraph, United Kingdom - Aug 4, 2008
Earlier this week Elan also reported disappointing results from its Alzheimer's treatment AAB-001, which resulted in a share slump. ...
Elan Jumps into Recovery Mode Investerms.com
No mercy from a sceptical market Irish Times
Risks Run High For Biogen, Elan Forbes
Bloomberg - Wall Street Journal Blogs
all 217 news articles »  ELN - PINK:ELNCF - BIIB

TheMedGuru
Scots Create Drug to Halt Alzheimer's Pill is 'Biggest ...
RedOrbit, TX -
Prof Wischik, who cofounded TauRx Therapeutics, which is developing the treatment, said: "This is an unprecedented result in the treatment of Alzheimer's. ...
Alzheimer's brings heartache to millions but a breakthrough by a ... Scotsman
Rember, the drug that helps alzheimers sufferers Times Online
Experimental Alzheimer's drug shows early promise Dallas Morning News
The Times - Chicago Tribune
all 48 news articles »
New Alzheimer's treatment slows mental decline, study shows
Chicago Tribune, United States - Jul 29, 2008
By Jeremy Manier | Chicago Tribune reporter A new treatment for Alzheimer's disease significantly slowed elderly patients' mental decline and may have ...
Anti-tau drug shows early promise in Alzheimer treatment Xinhua
Health: Treatment heralds Alzheimer's breakthrough guardian.co.uk
Breakthrough drug fights Alzheimer's The Press Association
Wired News - CBC.ca
all 630 news articles »

MedPage Today
Cutting-Edge Alzheimer's Treatment
ABC News - Jul 29, 2008
More than 5 million Americans have Alzheimer's disease and 10 million baby boomers are expected to develop it in the coming years, which is why there's so ...
Baxter boosted by drug's head start Chicago Tribune
Dimebon Shines as Alzheimer's Therapy WebMD
Diverse Approaches to Alzheimer's Therapies Continue to Show ... MarketWatch
Reuters - MarketWatch
all 85 news articles »  MDVN - BAX - OTC:CMTX
Aging population places demands on society
Calgary Herald,  Canada -
There has never been a bigger need for cheap, effective treatment for diseases of the old, such as Alzheimer's, or for easier access to pain relief and ...
Caution Urged on Alzheimer?s Drug Speculation
Senior-Spectrum, CA -
And Enbrel has not been approved for the treatment of Alzheimer?s disease. The use of the drug by Dr. Tobinick is ?off label? ? a term that refers to the ...

Oneindia
New drug boosts brain function in Alzheimer's patients
ABC Online, Australia - Jul 29, 2008
ASHLEY HALL: In the search for a treatment for Alzheimer's disease, researchers face the tough task of trying to find a drug that will both stop the disease ...
Study: Exercise slows Alzheimer's brain atrophy The Associated Press
Drugs to reverse Alzheimer's disease prove elusive Los Angeles Times
Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show ... FOXBusiness
University of British Columbia - Los Angeles Times
all 676 news articles »
The worrying prospect of losing your memory
Irish Times, Ireland -
I am worried in case I am developing dementia or Alzheimer's disease? A Not being able to immediately remember names and not picking up all the details of a ...
Amyloid beta mAb shows safety and perhaps efficacy in Alzheimer's ...
Medicexchange, UK -
Phase 2 results presented this week at the International Conference on Alzheimer's Disease (ICAD) 2008 in Chicago show that a monoclonal antibody to amyloid ...
Source: Google News

… -tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study … -
M Sano, C Ernesto, RG Thomas, MR Klauber, K … - N Engl J Med, 1997 - ncbi.nlm.nih.gov
... CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease,
treatment with selegiline or alpha-tocopherol slows the progression of ...

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer?s disease -
M Sano, C Ernesto, RG Thomas, MR Klauber, K … - N Engl J Med, 1997 - Mass Med Soc
... Sano M et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment
for Alzheimer's disease. N Engl J Med 1997 Apr 24 336 1216-1222. ...

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the … -
GW Small, PV Rabins, PP Barry, NS Buckholtz, ST … - JAMA, 1997 - Am Med Assoc
... Diagnosis and treatment of Alzheimer disease and related disorders. Consensus
statement of the American Association for Geriatric ...

… vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment … -
HC Chui - Neurology, 1992 - AAN Enterprises
... Criteria for the diagnosis of ischemic vascular dementia proposed by the State of
California Alzheimer's Disease Diagnostic and Treatment Centers. ...

Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. -
B Reisberg, J Borenstein, SP Salob, SH Ferris, E … - J Clin Psychiatry, 1987 - ncbi.nlm.nih.gov
J Clin Psychiatry. 1987 May;48 Suppl:9-15. Behavioral symptoms in Alzheimer's
disease: phenomenology and treatment. Reisberg B, Borenstein ...

Alzheimer's disease: etiologies, pathophysiology, cognitive reserve, and treatment opportunities -
JL Cummings - Neurology, 1998 - AAN Enterprises
... Neurology. VIEWS & REVIEWS. Alzheimer's disease: etiologies, pathophysiology,
cognitive reserve, and treatment opportunities. JL Cummings ...

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices … -
G McKhann - Neurology, 1984 - AAN Enterprises
... Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group
under the auspices of Department of Health and Human Services Task Force on ...

Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease A Randomized … -
RA Mulnard, CW Cotman, C Kawas, CH van Dyck, M … - JAMA, 2000 - Am Med Assoc
... Context Several reports from small clinical trials have suggested that estrogen
replacement therapy may be useful for the treatment of Alzheimer disease (AD ...

Memantine in Moderate-to-Severe Alzheimer's Disease -
B Reisberg, R Doody, A Stoffler, F Schmitt, S … - New England Journal of Medicine, 2003 - content.nejm.org
... Accordingly, we investigated memantine, an NMDA antagonist, for the treatment of
Alzheimer's disease. ... New Drug Offers Hope As Alzheimer's Treatment. Psychiatr. ...

Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer … -
J Poirier, MC Delisle, R Quirion, I Aubert, M … - Proceedings of the National Academy of Sciences of the …, 1995 - pubmedcentral.nih.gov
... 12264. Copyright notice. Apolipoprotein E4 allele as a predictor of cholinergic
deficits and treatment outcome in Alzheimer disease. J ...

Source: Google Scholar

Future Treatment Of Alzheimer's
A research with experimental rats carried out by the Institute of Neuroscience of the UAB describes the brain region connected to how our declarative memory functions. According to this experiment, part of the prefrontal cortex plays a key role in the social transmission of food preference. This research has helped learn more about how this type of memory functions. In the future, this information could be useful to find new treatment for diseases that affect the memory, such as Alzheimer's disease.

Declarative memory is described as a flexible, conscience and associative type of memory (i.e., it is based on relations between different stimuli). It differs from other types of memories that allow us to recall effective or emotionally-charged data, or carry out processes such as riding a bicycle or playing an instrument. Declarative memory allows us to remember things such as specific moments of our lives, names of people, what we ate for lunch, the capitals of the world, etc. The malfunctioning of this type of memory is one of the most common symptoms found in those suffering from Alzheimer's disease.
A useful model from which to learn about how declarative memory functions is the social transmission of food preference. In other species, this task is connected to the survival of the species and plays a crucial role in their evolution. In this research, the social transmission of food preference was carried out with experimental rats.

When one rodent sniffs another rodent's snout right after the second one has eaten, the first one will later choose to eat the same exact food. Animals learn to remember what their congeners eat and, in that way, lower the risk of eating new foods that could be harmful to them. In addition, they must later use this information acquired during a brief episode of social interaction in very different circumstances. Therefore, they need the flexible expression of memory, which is one of the main traits of declarative memory.

This task depends on learning how to associate smells, a function that is commanded by a specific region of the brain, the nucleus basalis magnocellularis (NBM), which produces acetylcholine (a neurotransmitter that "transfers information" from one neurone to another through synapses). This chemical substance is essential in making the memory work correctly. The nucleus basalis magnocellularis equivalent in humans is the nucleus basalis Meynert. Precisely this is one of the regions of the brain that shown signs of degeneration among those who suffer from Alzheimer's (and who are often treated with drugs that help to produce acetylcholine).

The acetylcholine produced by the nucleus basalis is transferred to other regions of the brain, where it is "recognised" by receptor molecules. The research team examined the possibility of one part of the brain, the prelimbic prefrontal cortex, being linked to the social transmission of food preference. To do so, they applied a chemical compound to the experimental rats that neutralised the acetylcholine receptors (muscarinic cholinergic receptor) of this region. By blocking the receptor, the effect of the neurotransmitter was also neutralised and the changes in the animals' behaviour were observed.

The results demonstrated that the social transmission of food preference was clearly affected after neutralising the acetylcholine receptors. Researchers also verified that the effects were not due to other aspects that could alter the experiment, such as lack of olfactory perception, motivation or social interaction. The results therefore suggest that the prelimbic prefrontal cortex, via the use of acetylcholine, regulates cognitive operations (e.g. flexibility in behaviour, attention or strategic planning) that could be needed to correctly express social transmission of food preference, and therefore necessary for our declarative memory.

Source: Gemma Guillazo
Universitat Autonoma de Barcelona
 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.